Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Antibody–drug conjugates (ADC) are designed to be stable in circulation and to release potent cytotoxic drugs intracellularly following antigen-specific binding, uptake, and degradation in tumor cells. Efficient internalization and routing to lysosomes where proteolysis can take place is therefore essential. For many cell surface proteins and carbohydrate structures on tumor cells, however, the magnitude of these processes is insufficient to allow for an effective ADC approach. We hypothesized that we could overcome this limitation by enhancing lysosomal ADC delivery via a bispecific antibody (bsAb) approach, in which one binding domain would provide tumor specificity, whereas the other binding domain would facilitate targeting to the lysosomal compartment. We therefore designed a bsAb in which one binding arm specifically targeted CD63, a protein that is described to shuttle between the plasma membrane and intracellular compartments, and combined it in a bsAb with a HER2 binding arm, which was selected as model antigen for tumor-specific binding. The resulting bsHER2xCD63his demonstrated strong binding, internalization and lysosomal accumulation in HER2-positive tumor cells, and minimal internalization into HER2-negative cells. By conjugating bsHER2xCD63his to the microtubule-disrupting agent duostatin-3, we were able to demonstrate potent cytotoxicity of bsHER2xCD63his-ADC against HER2-positive tumors, which was not observed with monovalent HER2- and CD63-specific ADCs. Our data demonstrate, for the first time, that intracellular trafficking of ADCs can be improved using a bsAb approach that targets the lysosomal membrane protein CD63 and provide a rationale for the development of novel bsADCs that combine tumor-specific targeting with targeting of rapidly internalizing antigens. Mol Cancer Ther; 15(11); 2688–97. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trafficking and function of the tetraspanin CD63
Pols, M. S., & Klumperman, J. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.09.020 · Cited by 745 · cited 5×
“Although the biology of CD63 is not completely understood, CD63 has been described to regulate transport of other proteins typically through endocytosis (10).”
BackgroundMethodInfluentialChaparro-Riggers, J., Liang, H., DeVay, R. M., Bai, L., Sutton, J. E., Chen, W., Geng, T., Lindquist, K., Casas, M. G., Boustany, L. M., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.319764 · Cited by 171
GPI Transamidase and GPI anchored proteins: Oncogenes and biomarkers for cancer
Gamage, D. G., & Hendrickson, T. L. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.831024 · Cited by 63 · cited 1×
“Glycosylphosphatidylinositol (GPI) anchored proteins (3, 36), adhesion molecules (6) and integrins (7) often recycle back to the plasma membrane after endocytosis, with only a minor fraction being targeted for lysosomal degradation.”
Background
Cited by
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Self-citationUnlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Metadata
- Authors
- de Goeij, B. E. C. G., Vink, T., ten Napel, H., Breij, E. C. W., Satijn, D., Wubbolts, R., Miao, D., & Parren, P. W. H. I.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2016-11-01
- Volume
- 15
- Issue
- 11
- Pages
- 2688-2697
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2513494897
- Cited by
- 138
- References
- 3
- FWCI
- 7.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63. https://app.cochat.ai/papers/10.1158/1535-7163.mct-16-0364
- The paper
- de Goeij, B. E. C. G., Vink, T., ten Napel, H., Breij, E. C. W., Satijn, D., Wubbolts, R., Miao, D., & Parren, P. W. H. I. (2016). Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-16-0364
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.